BC Week In Review | Sep 27, 2019
Company News

FDA broadens approval for Exact's Cologuard

FDA approved colorectal cancer screening test Cologuard from Exact Sciences Corp. (NASDAQ:EXAS) for average-risk adults ages 45 and older. The non-invasive home-based stool test was marketed for average-risk adults 50 and older. Exact is working...
BC Extra | Sep 25, 2019
Company News

Sept. 24 Company Quick Takes: FDA approves smallpox vaccine; plus Epidyolex, Vitrakvi, Oral semaglutide, Takeda-Evotec, Guerbet-IBM Watson

FDA approves Bavarian Nordic’s smallpox/monkeypox vaccine  FDA approved Jynneos MVA-BN from Bavarian Nordic A/S (CSE:BAVA; Pink:BVNRY) to prevent smallpox and monkeypox, making the vaccine the only approved non-replicating smallpox vaccine in the U.S. and the...
BC Extra | Jul 30, 2019
Company News

How $2.8B Genomic Health deal catapults Exact beyond Cologuard

In a play to expand its international reach, its position with payers and its sales force, Exact Sciences is acquiring Genomic Health in a deal valued at $2.8 billion. The deal also helps accelerate a...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
BC Week In Review | Aug 31, 2018
Company News

Exact enlists Pfizer to boost Cologuard sales

Exact Sciences Corp. (NASDAQ:EXAS) gained $15.27 (31%) to $65.32 on Aug. 22 after partnering with Pfizer Inc. (NYSE:PFE) to co-promote Exact's Cologuard in the U.S. Exact hopes the partnership will drive adoption of the non-invasive...
BC Extra | Aug 22, 2018
Company News

Exact enlists Pfizer to boost Cologuard sales

Exact Sciences Corp. (NASDAQ:EXAS) gained $15.27 (31%) to $65.32 on Wednesday after partnering with Pfizer Inc. (NYSE:PFE) to co-promote Exact's Cologuard in the U.S. Exact hopes the partnership will drive adoption of the non-invasive stool...
BC Week In Review | Aug 3, 2018
Company News

Exact slides after Cologuard volume disappoints

Exact Sciences Corp. (NASDAQ:EXAS) sank $12.62 (21%) to $46.50 in after-hours trading Aug. 1 after reporting a smaller-than-expected volume of completed Cologuard tests in its 2Q18 earnings. Cologuard is a non-invasive stool DNA test for...
BC Extra | Aug 1, 2018
Company News

Exact slides after Cologuard test volume disappoints

Exact Sciences Corp. (NASDAQ:EXAS) sank $12.62 (21%) to $46.50 in after-hours trading Wednesday after reporting a smaller-than-expected volume of completed Cologuard tests in its 2Q18 earnings. Cologuard is a non-invasive stool DNA test for colorectal...
BC Week In Review | Jun 8, 2018
Company News

Exact up on earlier colon cancer screening recommendation

Exact Sciences Corp. (NASDAQ:EXAS) jumped $5.86 (11%) to $58.58 on May 30 when the American Cancer Society (ACS) issued updated guidelines recommending that screening for colorectal cancer start earlier. Exact markets Cologuard, a non-invasive stool...
Items per page:
1 - 10 of 104